Another study, from the Seoul National University College of Medicine, evaluated the use of toremifene as an adjuvant hormonal therapy for estrogen receptor positive early breast cancer patients in terms of its therapeutic efficacy and effect on the endometrium, as compared with tamoxifen, but the study did not consider how treatment affected these patients’ menstrual cycles. This evidence concerns the gene ESR1 and breast carcinoma.